DiscGenics Completes Enrollment in Discogenic Cell Therapy Clinical Trial

DiscGenics completed enrollment in its Phase I/II first-in-human U.S. clinical study of injectable disc cell therapy (IDCT), an allogeneic treatment for degenerative disc disease (DDD).

The two-year prospective, randomized, double-blinded, vehicle- and placebo-controlled, multicenter clinical study will examine IDCT in patients with...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us